All In MedTech

Device Trial Radar · NCT07917715

MacuMira Microcurrent Stimulation for Dark Adaptation in Dry Age-Related Macular Degeneration

MacuMira Microcurrent Electrical Stimulation and Dark Adaptation in Dry Age-Related Macular Degeneration

Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

50

Planned (sponsor's estimate)

Start

Nov 4, 2026

Primary completion

Aug 16, 2027

Study completion Oct 16, 2027

Sponsor

Lead sponsor
Clarity Eye InstituteAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
MacuMira
First posted
Nov 4, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Age-related macular degeneration (AMD) is an eye condition that affects the retina and can lead to progressive vision loss. This study will evaluate the effects of MacuMira microcurrent stimulation on dark adaptation in adults with intermediate dry AMD. Participants will receive four in-office treatment sessions over 10 to 14 days. Dark adaptation and other measures of visual function and retinal health will be assessed before treatment and at one and three months after treatment.

Conditions

  • Age-Related Macular Degeneration (AMD)

Interventions

  • Transpalpebral microcurrent electrical stimulationDevice

    Four in-office sessions of transpalpebral microcurrent electrical stimulation using the MacuMira device. The first treatment session will occur within 7 days of screening/baseline, with the remaining sessions administered over approximately 10 to 14 days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Rod Intercept Time (RIT) from Baseline to Month 1Time frame: Average of two baseline assessments (Screening/Baseline and Treatment Day 1) to the single assessment at Month 1.

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Clarity Eye Newmarket

    Newmarket, Ontario, Canada

2 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.